[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349876-105":59,"doc-detail-349876-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","braf-and-mek-inhibition-beyond-dabrafenib-trametinib-in-advanced-thyroid-cancer-a-real-world-case-series","BRAF and MEK inhibition beyond dabrafenib - trametinib in advanced thyroid cancer - a real-world case series","","Real-world experience is provided for treating advanced thyroid cancers harboring the BRAF V600E mutation using BRAF and MEK inhibitors other than dabrafenib and trametinib. Methods cover a four-patient case series with confirmed BRAF V600E (three papillary, one anaplastic). Partial responses occurred in all patients during therapy (ORR 100%), with stable disease across phases, but toxicity prompted dose changes. Despite initial activity, all progressed and required sequential strategies; overall survival ranged from 6.0 to 25.3 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/braf-and-mek-inhibition-beyond-dabrafenib-trametinib-in-advanced-thyroid-cancer-a-real-world-case-series/349876/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/braf-and-mek-inhibition-beyond-dabrafenib-trametinib-in-advanced-thyroid-cancer-a-real-world-case-series/349876.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the objective of the case series?","Question",{"text":112,"@type":113},"To describe real-world treatment experience using BRAF and MEK inhibitors other than dabrafenib and trametinib for advanced thyroid cancers with the BRAF V600E mutation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the patient cohort defined and what treatments were used?",{"text":117,"@type":113},"The study included four patients with advanced thyroid cancer (three papillary and one anaplastic) who all had confirmed BRAF V600E, treated with various BRAF and MEK inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes and complications were observed during therapy?",{"text":121,"@type":113},"All patients showed partial response during therapy (ORR 100%) and stable disease across phases, but significant toxicities led to dose reductions or discontinuations, and eventually all cases progressed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349876,1790257677,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Original Research PUBLISHED 05 February 2026 DOI 10.3389/fendo.2026.1694805  \nOPEN ACCESS  \nEDITED BY  \nDario de Biase,  \nUniversity of Bologna, Italy  \nREVIEWED BY  \nKrystallenia I. Alexandraki,  \nNational and Kapodistrian University of Athens, Greece  \nMarilda Mormando,  \nRegina Elena National Cancer Institute (IRCCS), Italy  \n*CORRESPONDENCE  \nTzahi Yamin  \n[yaminzack@gmail.com](yaminzack@gmail.com)  \nRECEIVED 28 August 2025  \nREVISED 09 November 2025  \nACCEPTED 19 January 2026  \nPUBLISHED 05 February 2026  \nCITATION  \nYamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N and Finkel I (2026) BRAF and MEK inhibition beyond dabrafenib–trametinib in advanced thyroid cancer: a real-world case series.  \nFront. Endocrinol. 17:1694805 .  \ndoi: 10.3389/fendo.2026.1694805  \nCOPYRIGHT  \n© 2026 Yamin, Cohen, Robenshtok, Izkhakov, Miodovnik, Gutfeld, Leshem, Meirovitz, Warshavsky, Muhanna and Finkel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBRAF and MEK inhibition beyond dabrafenib–trametinibin advanced thyroid cancer: areal-world case series  \nTzahi Yamin 1*, Oded Cohen 1, Eyal Robenshtok 2,  \nElena Izkhakov 3, Mor Miodovnik 4, Orit Gutfeld 4, Yasmin Leshem 4, Roman Meirovitz 4, Anton Warshavsky5, Nidal Muhanna 5 and Inbar Finkel 4  \n1 Department of Otolaryngology, Head and Neck Surgery, Assuta Samson Ashdod Medical Center, Ashdod, Israel, 2 Endocrinology and Metabolism Institute and Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, 3 Institute of Endocrinology, Metabolism and Hypertension, Sourasky Medical Center, Tel Aviv, Israel, 4Oncology Division, Sourasky Medical Center, Tel Aviv, Israel,  \n5 Department of Otolaryngology, Head and Neck Surgery and Maxillofacial Surgery, Sourasky Medical Center, Tel Aviv, Israel  \nObjective: BRAF V600E mutation is the most common and clinically significant genetic alteration in advanced thyroid cancers. This study provides real-world experience with BRAF and MEK inhibitors other than dabrafenib and trametinib in the treatment of advanced thyroid cancers harboring this mutation.  \nMethods: A case series of four patients with advanced thyroid cancer (three papillary and one anaplastic) treated with various BRAF and MEK inhibitors. All patients had confirmed BRAF V600E mutation.  \nResults: Among three patients treated with BRAF/MEK inhibitors for radioiodine refractory metastatic PTC, and one patient with ATC, all (100%) demonstrated a partial response (PR) during therapy, yielding an overall response rate (ORR) of 100% . Stable disease was observed in multiple treatment phases, contributing toa high overall disease control rate. Three patients had disease-related death, while one remained under treatment at last follow-up. The course of treatment was complicated by significant toxicities, leading to dose reductions or treatment discontinuations. Despite initial responses, all cases eventually progressed, necessitating sequential treatment strategies. Overall survival ranged from 6 .0 to 25.3 months, with a median follow-up of 18.3 months since the initiation of BRAF and MEK inhibitors.  \nConclusions: This case series highlights the potential benefits and challenges of targeted therapies in advanced thyroid cancer. While BRAF and MEK inhibitors offer new treatment options, toxicity management and the development of resistance remain significant hurdles. The limited FDA-approved options for BRAF V600E-positive thyroid cancer compared to melanoma underscore the need for further research to optimize and expand treatment st","cbCaiiCPFhgANlT9","https://ap.wps.com/l/cbCaiiCPFhgANlT9","pdf",1348647,"English","# Introduction\n## Thyroid cancer background and mutation relevance\n# Methods\n## Patient selection and treatment approach\n# Results\n## Response rate, disease control, toxicity, and progression\n# Conclusions\n## Clinical implications and remaining challenges","[{\"question\":\"What is the objective of the case series?\",\"answer\":\"To describe real-world treatment experience using BRAF and MEK inhibitors other than dabrafenib and trametinib for advanced thyroid cancers with the BRAF V600E mutation.\"},{\"question\":\"How was the patient cohort defined and what treatments were used?\",\"answer\":\"The study included four patients with advanced thyroid cancer (three papillary and one anaplastic) who all had confirmed BRAF V600E, treated with various BRAF and MEK inhibitors.\"},{\"question\":\"What outcomes and complications were observed during therapy?\",\"answer\":\"All patients showed partial response during therapy (ORR 100%) and stable disease across phases, but significant toxicities led to dose reductions or discontinuations, and eventually all cases progressed.\"}]","BRAF and MEK inhibition beyond dabrafenib - trametinib in advanced thyroid cancer - a real-world case series | PDF",1790086055,25]